The study identified that PTPRG-AS1, regulated by POU2F2, modulates ferroptosis and proliferation in TNBC via the miR-376c-3p/SLC7A11 axis, highlighting its potential as a therapeutic target for TNBC treatment. The POU2F2/PTPRG-AS1/miR-376c-3p/SLC7A11 axis holds potential as novel biomarkers and therapeutic targets for ferroptosis-mediated cancer therapy in TNBC. The gene discussed is SLC7A11; the disease is cancer.